StockData
Recursion Pharmaceuticals, Inc. logo

Recursion Pharmaceuticals, Inc. (RXRX) stock

RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/302% below fair value
$2.90−0.28 (-8.79%)

Close on Nov 16, 2026Market cap $1.56BP/E –Yield –

Earnings

Recursion Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 24, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q2 FY2026
$7.70M
-59.9% on a year earlier
EPS, Q2 FY2026
-$0.25
-$0.41 a year earlier
Latest guidance
Lowered
Aug 5, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Recursion Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 24, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Oct 15, 2026before the open–––Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026before the open$7.70M-59.9%-$0.25Release
Q1 FY2026ended Mar 31, 2026May 6, 2026before the open$6.50M-56.7%–Release
Q4 FY2025ended Dec 31, 2025Feb 25, 2026before the open$35.50M+688.9%–Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025before the open$5.20M-80.1%–Release
Q2 FY2025ended Jun 30, 2025Aug 5, 2025before the open$19.20M–-$0.41Release
Q1 FY2025ended Mar 31, 2025May 5, 2025before the open$15.00M+8.7%–Release
Q4 FY2024ended Dec 31, 2024Feb 28, 2025before the open$4.50M-58.7%–Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024after the close$26.10M+148.6%–Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024before the open–––Release
Q1 FY2024ended Mar 31, 2024May 9, 2024after the close$13.80M+14.0%-$0.39Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Recursion Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
cash operating expensenon-GAAPFY2026$375.00M–LoweredAug 5, 2026
operating cash expense, excluding partnership inflows and transaction costsnon-GAAPFY2026$390.00M–NewFeb 25, 2026
operational cash burnFY2026$390.00M–NewMay 6, 2026

Guidance history

Every forecast Recursion Pharmaceuticals put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 5, 2026cash operating expenseFY2026$375.00MLowered
May 6, 2026operational cash burnFY2026$390.00MNew
Feb 25, 2026operating cash expense, excluding partnership inflows and transaction costsFY2026$390.00MNew
May 5, 2025cash burnFY2025$450.00MNew
Feb 28, 2025synergiesFY2025$100.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Recursion Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Results
  6. Results
  7. Results
  8. Results
  9. Results
  10. Results
  11. Results
  12. Update
  13. Update
  14. Results
  15. Results

See a number that looks wrong?